Business · 28/08/2018Updated: 10/17/2026 · 1 min read

FDA Proposes Removal of Three Bulk Drug Substances from 503B Bulks List

Summary

The FDA is proposing not to include bumetanide, nicardipine hydrochloride, and vasopressin on the 503B Bulks List, a list of bulk drug substances for which there is a clinical need, and is considering additional substances nominated by the public.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Business insights →

Healthcare Business News Global Markets News Trade Regulation News Business Technology News Fintech for Business: Payments & Banking News Supply Chain News

Related business signals

Business · 9/17/2026

Proposed Data Collection Activity for Diaper Distribution Demonstration and Research Pilot Beneficiary and Organizational Survey

The Administration for Children and Families, Department of Health and Human Services, is proposing to continue collecting data on diaper need and outcomes for beneficiaries of the Diaper Distribution Demonstration and Research Pilot, with proposed changes to the Beneficiary Survey and addition of an Organizational Survey.

Read summary →

Business · 9/16/2026

Microbiology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Pathogen-Agnostic Sequencing

The Food and Drug Administration (FDA) announces a public advisory committee meeting of the Microbiology Devices Panel to discuss pathogen-agnostic sequencing for emergency preparedness and response efforts.

Read summary →

Business · 9/16/2026

NIH Proposed Collection; 60-Day Comment Request; NIH Intramural Reporting of Research Misconduct (IRRM) Web Form

The National Institutes of Health (NIH) is proposing a web-based reporting form to help the Agency Intramural Research Integrity Officer (AIRIO) assess concerns and determine appropriate next steps in evaluating allegations of research misconduct.

Read summary →

Business · 9/16/2026

Food and Drug Administration Announces Proposed Collection of Information for Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturing

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Read summary →

Business · 9/16/2026

Medicare Program; Public Meeting for New Revisions to the Healthcare Common Procedure Coding System (HCPCS) Level II Coding

The Centers for Medicare and Medicaid Services (CMS) will hold its second biannual Healthcare Common Procedure Coding System (HCPCS) Level II public meeting of 2026 to discuss new revisions to the HCPCS Level II code set for non-drug and non-biological items and services.

Read summary →

Business · 9/15/2026

FDA Establishes Public Docket for Rare Disease Clinical Investigations Statistical Considerations

The FDA is collecting feedback on statistical considerations for rare disease clinical investigations through a public docket, which is open until a certain date, and a Rare Disease Innovation, Science, and Exploration (RISE) Workshop on the topic.

Read summary →